SCHEMBL12215320

SCHEMBL12215320

COc1ccc(Br)c2[nH]cc(C(=O)C(C)=O)c12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.41
▸ ALDH1A1 P00352 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ HPGD P15428 3/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ CYP2C9 P11712 1/20 0.36
▸ ERN1 O75460 1/20 0.35
▸ LCK P06239 1/20 0.34
▸ FYN P06241 1/20 0.34
▸ MAPT P10636 1/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MTNR1A P48039 2/20 0.32
▸ MTNR1B P49286 2/20 0.32
▸ NR4A2 P43354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12215131 0.87 CNR1 (0.40) CYP3A4ALDH1A1KDM4EHPGDCNR1
SCHEMBL12215333 0.83 KDM4E (0.47) CYP3A4ALDH1A1KDM4EHPGDCNR1
SCHEMBL12215330 0.83 CYP3A4 (0.41) CYP3A4ALDH1A1KDM4EHPGDCNR1
SCHEMBL13555236 0.83 CYP3A4 (0.41) CYP3A4ALDH1A1KDM4EHPGDCNR1
SCHEMBL31708112 0.82 GABRP (0.42) CNR1CNR2MAPTL3MBTL1
SCHEMBL13555232 0.80 CYP2C9 (0.49) CYP3A4ALDH1A1KDM4EHPGDCYP2C9
SCHEMBL12215433 0.80 ALDH1A1 (0.43) CYP3A4ALDH1A1KDM4EHPGDCNR1
SCHEMBL13325438 0.79 BRPF1 (0.33) ALDH1A1
SCHEMBL13554652 0.79 CYP2C9 (0.48) CYP3A4ALDH1A1KDM4ECNR1CNR2
SCHEMBL12215340 0.79 GAA (0.43) CYP3A4ALDH1A1KDM4EHPGDCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039486-B2 Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-18 — — US disclosed
US-20080132516-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132516-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES IDO2, IDO1, INMT CYP3A4 136/4885ALDH1A1 2529/4885KDM4E 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback